Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics

The aim of this post-marketing surveillance (PMS) study is to evaluate the real-world safety and efficacy of CT-P13, the first biosimilar of infliximab (IFX). Japanese patients with rheumatoid arthritis were prospectively registered from November 2014 and followed up for 1 year. Of 794 patients in t...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2022-07, Vol.32 (4), p.718-727
Main Authors: Takeuchi, Tsutomu, Nishikawa, Kiyohiro, Yamada, Fumika, Ohshima, Shiro, Inoue, Makoto, Yoshioka, Yutaka, Yamanaka, Hisashi
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this post-marketing surveillance (PMS) study is to evaluate the real-world safety and efficacy of CT-P13, the first biosimilar of infliximab (IFX). Japanese patients with rheumatoid arthritis were prospectively registered from November 2014 and followed up for 1 year. Of 794 patients in the analysis set, 318 patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) showed an immediate decrease in Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP) and increased remission rate (DAS28-CRP
ISSN:1439-7595
1439-7609
DOI:10.1093/mr/roab068